Cytokine Gene Transfer for Metastatic Colorectal Cancer

Information

  • Research Project
  • 6774744
  • ApplicationId
    6774744
  • Core Project Number
    R43CA102806
  • Full Project Number
    5R43CA102806-02
  • Serial Number
    102806
  • FOA Number
    PA-01-91
  • Sub Project Id
  • Project Start Date
    7/10/2003 - 21 years ago
  • Project End Date
    6/30/2008 - 16 years ago
  • Program Officer Name
    FU, YALI
  • Budget Start Date
    7/26/2004 - 20 years ago
  • Budget End Date
    6/30/2008 - 16 years ago
  • Fiscal Year
    2004
  • Support Year
    2
  • Suffix
  • Award Notice Date
    7/26/2004 - 20 years ago

Cytokine Gene Transfer for Metastatic Colorectal Cancer

DESCRIPTION (provided by applicant): Metastatic colon cancer represents a significant healthcare problem in the U.S., with 50,000 new cases diagnosed annually and median survival at less than 2 years. The identification of tumor-associated antigens in colon cancer provides the basis to evaluate immunological treatment strategies. Despite showing promise in some cancers, immunotherapy using systemic cytokine administration has largely disappointed due to low response rates and high toxicity. Intratumoral gene transfer has been proposed as an alternative means of administration to improve the therapeutic and toxicologic profile of these molecules. Unfortunately, clinical implementation is hampered by the lack of clinically viable gene delivery vectors. Recent studies of in vivo electroporation demonstrate dramatic improvement in intratumoral delivery of therapeutic agents. Ichor has developed proprietary electroporation technology enabling safe and effective application of the procedure. Initial preclinical work suggests that Ichor's system is a promising means for intratumoral cytokine gene delivery. Under FLAIR Phase-l, Ichor will evaluate its electroporation technology for delivery of cytokine genes into hepatic colon cancer metastases. Research will include rodent studies designed to establish effective treatment protocols. Successful completion will lead to formal toxicology studies and subsequent clinical investigation of the procedure in patients with unresectable colorectal metastases, conducted under FLAIR Phase-lI.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    248375
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:248375\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ICHOR MEDICAL SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92121
  • Organization District
    UNITED STATES